Table III.
Characteristics of patients for follow-up.
| Patients | Age/sex | Stage | Pathology | Therapy |
|---|---|---|---|---|
| 40 | 62/M | II B | Squamous | Radical procedure |
| 74 | 45/F | II A | Adeno | Radical procedure |
| 79 | 55/M | III A | Adeno | Radical procedure |
| 161 | 41/F | II A | Adeno | Radical procedure |
| 181 | 62/M | III A | Adeno | Radical procedure |
| 299 | 48/M | III B | Adeno | Radical procedure |
| 41 | 56/M | III A | Squamous | Chemotherapy (NP) |
| 43 | 62/F | III B | Adeno | Chemotherapy (TP) |
| 298 | 41/M | IV | Adeno | Chemotherapy (TP) |
Squamous, squamous cell carcinoma; adeno, adenocarcinoma; NP, vinorelbine and cisplatin (vinorelbine for 25 mg/m2 and cisplatin for 75 mg/m2); TP, docetaxel and cisplatin (docetaxel for 75 mg/m2 and cisplatin for 75 mg/m2).